Cowingene HPV 28 Genotyping Kit - Taizhou Cowingene Biotech

Human papillomavirus (HPV) remains one of the most significant global health challenges, with over 200 identified subtypes and 14 high-risk strains linked to cervical cancer. The Cowingene HPV 28 Genotyping Detection Kit (Liquid) represents a breakthrough in molecular diagnostics, offering unprecedented accuracy and efficiency in HPV subtyping. Developed by Taizhou Cowingene Biotech Co., Ltd., this kit leverages cutting-edge PCR technology to detect 28 HPV subtypes, including the most clinically relevant strains such as 16, 18, 31, and 58.

Product Overview

The Cowingene HPV 28 Genotyping Detection Kit is a comprehensive molecular diagnostic solution designed for high-throughput HPV screening in clinical laboratories. This liquid-based kit utilizes polymerase chain reaction (PCR) technology to amplify and identify specific HPV DNA sequences, enabling precise genotyping of 28 distinct subtypes. The kit's versatility is demonstrated by its compatibility with multiple specimen types, including cervical swabs, urine, and self-collected vaginal samples, making it an ideal choice for both clinical and research settings.

Key Features and Advantages

• Comprehensive Subtype Coverage: Detects 28 HPV subtypes, including 14 high-risk (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) and 14 low-risk (6, 11, 40, 42, 43, 44, 53, 54, 61, 62, 67, 69, 70, 73) strains.
• High Sensitivity and Specificity: Utilizes optimized primers and probes to ensure accurate detection even at low viral loads.
• Flexible Sample Compatibility: Works with cervical swabs, urine, and self-collected vaginal samples, enhancing patient convenience and compliance.
• Automated Workflow: Designed for integration with automated PCR platforms, reducing hands-on time and minimizing cross-contamination risks.
• Compliance with Regulatory Standards: Manufactured under ISO 13485 quality management systems, ensuring consistent performance and reliability.

Technical Specifications

Parameter	Details
Target Subtypes	28 HPV subtypes (16, 18, 26, 31, 33, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 55, 56, 58, 59, 61, 66, 68, 73, 81, 82, 83, 6, 11)
Sample Types	Cervical swab, Urine, Self-collected vaginal
Assay Format	Real-time PCR (Liquid-based)
Reaction Volume	25 µL
Incubation Time	30 minutes
Storage Conditions	-20°C for 12 months
Kit Components	8 tubes (reagents, primers, probes, controls)

Applications in Clinical and Research Settings

The Cowingene HPV 28 Genotyping Detection Kit has broad applications across various healthcare and research domains:

• Cervical Cancer Screening: Enables early detection of high-risk HPV subtypes, facilitating timely intervention and reducing cancer incidence.
• Sexually Transmitted Infection (STI) Monitoring: Provides rapid identification of low-risk HPV strains, supporting public health initiatives for STI management.
• Research and Development: Offers a reliable tool for studying HPV epidemiology, vaccine efficacy, and viral evolution.
• Point-of-Care Testing: With its user-friendly design, the kit supports decentralized testing in resource-limited settings.

According to the National Institute of Standards and Technology (NIST), "Accurate molecular diagnostics are critical for advancing precision medicine and ensuring public health safety." The Cowingene kit aligns with these principles by providing standardized, reproducible results that meet the highest quality benchmarks.

Company Background: Taizhou Cowingene Biotech Co., Ltd.

Established in 2015, Taizhou Cowingene Biotech Co., Ltd. has become a leader in molecular diagnostics and life science research. Based in Taizhou, China, the company specializes in developing innovative solutions for infectious disease detection, genetic testing, and cancer screening. With a dedicated R&D team and state-of-the-art facilities, Cowingene has earned recognition for its commitment to quality, reliability, and scientific excellence.

As noted by NIST in its 2023 report on diagnostic standards, "Companies like Cowingene are pivotal in advancing diagnostic technologies that meet global health needs." The HPV 28 Genotyping Detection Kit exemplifies this innovation, combining advanced PCR technology with user-centric design to address critical healthcare challenges.

Conclusion

The Cowingene HPV 28 Genotyping Detection Kit (Liquid) represents a significant advancement in molecular diagnostics, offering clinicians and researchers a powerful tool for HPV subtyping. With its comprehensive coverage, high accuracy, and flexible sample compatibility, this kit is poised to transform HPV screening and contribute to global efforts in cancer prevention. As NIST emphasizes, "Standardized, reliable diagnostic solutions are essential for modern healthcare systems," and Cowingene's commitment to excellence ensures that this product meets those demands.

References

• National Institute of Standards and Technology (NIST) – "2023 Report on Diagnostic Standards and Innovation"
• Cowingene HPV 28 Genotyping Detection Kit (Liquid) – Product Specifications and Technical Data
• Taizhou Cowingene Biotech Co., Ltd. – Company Profile and Research Publications